Zum Inhalt springen

Umoja Biopharma Announces Appointment of Britton Russell as Chief Financial Officer

SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) — Umoja Biopharma, Inc., (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T cell therapies in oncology and autoimmunity, today announced the appointment of Britton Russell as Chief Financial Officer. Mr. Russell brings a wealth of experience working with both emerging growth companies and large multinational organizations to support long-term growth objectives. Umoja Biopharma Announces Appointment of Britton Russell as Chief Financial Officer

Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA® in Most of Their Stores Throughout the U.S.

PALO ALTO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced a major initiative with a leading national pharmacy chain to stock GLOPERBA® in most of their stores throughout the U.S.  GLOPERBA®, an FDA-approved prophylactic treatment for painful gout flares in adults in the U.S., is expected to launch in the U.S. in first half of 2024. The increase of GLOPERBA® manufacturing is to meet its potential demand and increased stocking needs in its distribution center. Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA® in Most of Their Stores Throughout the U.S.

Biomarker predicts sudden cardiac death in men

The discovery of a biomarker readily measured in blood could be a significant step towards preventing sudden deaths. Plasma 4?-hydroxycholesterol (4?HC) measurement could offer a possibility to predict and prevent sudden cardiac deaths in men with coronary artery disease, according to a study by the University of Oulu, Finland. The study found that high levels of 4?HC were associated with total mortality, cardiac mortality and especially sudden cardiac death in men. The significance of 4?HC levels has not been previously studied in patients with coronary artery disease.

LabNews

Deutschlands Labormedizin lässt sich per APT ausschalten

Das deutsche Gesundheitssystem kann innerhalb weniger Tage kollabieren: Kaum ein labormedizinisches Institut – Universitätsklinik oder privat – ist gegen Advanced Persistent Threat (APT) Angriffe gerüstet. Zwar verwenden alle Einrichtungen zertifizierte Cybersicherheits-Lösungen, die den Vorgaben des BSI entsprechen. Einzig nur: Diese reichen nach Insiderinformationen von LabNews nicht aus, um neue oder beriets bestehende APTs zu entdecken.

Fehler in der Belüftung des Operationssaals erhöht COVID-19 Risiko

Die in der Zeitschrift Life Journal veröffentlichte Studie „Ventilation-Based Strategy to Manage Intraoperative Aerosol Viral Transmission in the Era of SARS-CoV-2“ begann mitten in der Pandemie, um die Effizienz von Beatmungssystemen in Operationssälen zu bestimmen, in denen ein COVID-19-Virus diagnostiziert wurde Dabei wurde ein positiver Patient behandelt. In Zusammenarbeit mit Chirurgen der Cleveland Clinic Abu Dhabi nutzte das NYUAD-Forschungsteam unter der Leitung von Mohammad Qasaimeh, Direktor des Advanced Microfluidics and Microdevices Laboratory (AMMLab) der Universität, experimentelle und rechnergestützte technische Werkzeuge, um den Luftstrom in aktiven Operationssälen zu untersuchen. Die Übertragung luftübertragener Keime von Patienten auf Operationsteams ist ein großes Problem, das während der COVID-19-Pandemie noch verschärft wurde, als weltweit Millionen von geplanten Operationen aus Sicherheitsgründen abgesagt oder verschoben wurden. Beatmungssysteme dienen in erster Linie dazu, Patienten vor Luftverschmutzung und Infektionen der Operationsstelle zu schützen, indem sie die Luft aus dem… 

more »Fehler in der Belüftung des Operationssaals erhöht COVID-19 Risiko

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB). MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

Neue KI-gestützte biomedizinische Wissensdatenbank: QIAGEN beschleunigt datenbasierte Arzneimittelforschung

QIAGEN Biomedical KB-AI enthält mehr als 640 Millionen biomedizinische Beziehungen, darunter Kausalzusammenhänge zwischen Genen, Krankheiten und Medikamenten, zur Beschleunigung der datenbasierten Arzneimittelforschung // Ergänzt von Menschen kuratierte QIAGEN Biomedical KB-HD und hilft bei der Identifizierung neuer Zusammenhänge zwischen Krankheiten, biologischen Signalwegen und molekularen Wechselwirkungen, die mit herkömmlichen Methoden übersehen werden können // Workflow verkürzt die Hypothesenprüfung und beschleunigt die Identifizierung vielversprechender therapeutischer Wege mit klaren, strukturierten Daten Neue KI-gestützte biomedizinische Wissensdatenbank: QIAGEN beschleunigt datenbasierte Arzneimittelforschung

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

Highlights: Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET

HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET

QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery

QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven drug discovery // AI-driven insights complement human-curated QIAGEN Biomedical KB-HD and help identify novel relationships between diseases, biological pathways and molecular interactions that may be missed by traditional methods // Workflow cuts down on hypothesis testing time and speeds up the identification of promising therapeutic avenues with clear, structured data QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven drug discovery // AI-driven insights complement human-curated QIAGEN Biomedical KB-HD and help identify novel relationships between diseases, biological pathways and molecular interactions that may be missed by traditional methods // Workflow cuts down on hypothesis testing time and speeds up the identification of promising therapeutic avenues with clear, structured data… 

more »QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery